Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Dae Wook Hwang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1749-038X; OpenAlex author ID A5037596654. Sources: ClinicalTrials.gov.

Their work

Papers
67 (first author 6, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
106
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 5 papers · 2018: 4 papers · 2019: 7 papers · 2020: 9 papers · 2021: 9 papers · 2022: 8 papers · 2023: 6 papers, 1 trial · 2024: 6 papers · 2025: 4 papers · 2026: 5 papers, 1 trial

Papers 50 of 67

  1. Minimally invasive vs. open-extended distal pancreatectomy with multi-organ resection: postoperative and oncological outcomes for left-sided pancreatic ductal … First author DOI 10.1007/s00464-025-12452-3↗
  2. Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI characteristics and diagnostic implicat… Last author DOI 10.1016/j.ejrad.2026.112735↗
  3. Clinical outcomes of completing total pancreatectomy for isolated recurrence of pancreatic ductal adenocarcinoma in the remnant pancreas after initial pancreat… First author DOI 10.1016/j.surg.2026.110088↗
  4. Clinical Utility of Circulating Tumor DNA Analysis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/11795549261480247↗
  5. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  6. Applicability of current nodal staging system for resected pancreatic cancer after neoadjuvant therapy: a retrospective study. Co-author DOI 10.1016/j.hpb.2025.04.011↗
  7. Oncological outcomes of palliative minimally invasive distal pancreatectomy for unexpected metastatic pancreatic ductal adenocarcinoma: A single-center experie… First author DOI 10.1016/j.surg.2025.109331↗
  8. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
  9. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
  10. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  11. Computed tomography-based vascular burden index as a predictor of vascular resection and pathological vascular invasion in pancreatic cancer with neo-adjuvant … Co-author DOI 10.1016/j.ejso.2024.108494↗
  12. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  13. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000001389↗
  14. Prognostic model for resected borderline and locally advanced pancreatic cancer after neoadjuvant chemotherapy. Co-author DOI 10.1097/js9.0000000000001927↗
  15. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.977↗
  16. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1272↗
  17. Robotic versus laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1016/j.hbpd.2022.06.001↗
  18. Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002218↗
  19. 15-Year Experience of Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer-A Korean Nationwide Investigation. Co-author DOI 10.3390/cancers15153850↗
  20. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. First author DOI 10.4143/crt.2022.409↗
  21. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
  22. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  23. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Co-author DOI 10.1007/s00464-021-08627-3↗
  24. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIR… Co-author DOI 10.1016/j.esmoop.2022.100484↗
  25. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Co-author DOI 10.1016/j.ijsu.2022.106851↗
  26. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  27. Predictive Performance of Current Nodal Staging Systems in Various Categories of Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10641-7↗
  28. Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review. Co-author DOI 10.21037/cco-21-166↗
  29. Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfron… First author DOI 10.21037/gs-22-304↗
  30. A comparison of minimally invasive vs open distal pancreatectomy for resectable pancreatic ductal adenocarcinoma: Propensity score matching analysis. Co-author DOI 10.1002/jhbp.853↗
  31. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-020-80383-1↗
  32. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Co-author DOI 10.1093/bjs/znab229↗
  33. Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadren… Co-author DOI 10.3390/biomedicines9101291↗
  34. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker… Co-author DOI 10.3390/biomedicines9111599↗
  35. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Co-author DOI 10.3390/biomedicines9111706↗
  36. Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/jcm10245784↗
  37. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v13.i11.1423↗
  38. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  39. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  40. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. Co-author DOI 10.1038/s41598-020-68703-x↗
  41. Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients. Co-author DOI 10.1097/md.0000000000022115↗
  42. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  43. Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to panc… Co-author DOI 10.14701/ahbps.2020.24.2.127↗
  44. Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors. Co-author DOI 10.3390/cancers12010137↗
  45. Comparison of Minimally Invasive Versus Open Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Matching Analysis. Co-author DOI 10.3390/cancers12040982↗
  46. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderli… Co-author DOI 10.3390/jcm9051477↗
  47. Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm9061953↗
  48. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/bjs.11144↗
  49. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy. Co-author DOI 10.1002/jhbp.627↗
  50. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic D… Co-author DOI 10.1097/mpa.0000000000001255↗

Trials 2

  1. Postoperative Insulin Intervention After Pancreatectomy in nDM Patients Principal investigator NCT07540975↗
  2. The Effect of ERAS on Pancreaticoduodenectomy (v2.0) Principal investigator NCT06009224↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Song Cheol Kim · 54 shared papers, 2014–2026 · strength 7.03
  2. Ki Byung Song · 51 shared papers, 2014–2026 · strength 7.00
  3. Woohyung Lee · 30 shared papers, 2020–2026 · strength 4.71
  4. Yejong Park · 28 shared papers, 2019–2026 · strength 4.53
  5. Changhoon Yoo · 24 shared papers, 2017–2026 · strength 3.18
  6. Eunsung Jun · 18 shared papers, 2017–2026 · strength 3.04
  7. Kyu‐pyo Kim · 23 shared papers, 2017–2026 · strength 2.99
  8. Baek‐Yeol Ryoo · 17 shared papers, 2017–2026 · strength 1.95
  9. Jaewoo Kwon · 15 shared papers, 2019–2023 · strength 1.78
  10. Seung‐Mo Hong · 13 shared papers, 2017–2025 · strength 1.71
  11. Tae Jun Song · 14 shared papers, 2017–2026 · strength 1.60
  12. Seung Soo Lee · 8 shared papers, 2020–2026 · strength 1.55
  13. Min Kyu Sung · 8 shared papers, 2021–2025 · strength 1.50
  14. Bong Jun Kwak · 10 shared papers, 2014–2024 · strength 1.44
  15. Sang Soo Lee · 14 shared papers, 2017–2024 · strength 1.40
  16. Jin‐hong Park · 12 shared papers, 2017–2026 · strength 1.36
  17. Jae Ho Byun · 7 shared papers, 2020–2026 · strength 1.30
  18. Sarang Hong · 10 shared papers, 2019–2023 · strength 1.22
  19. Dong Wan Seo · 11 shared papers, 2017–2025 · strength 1.21
  20. Hyoung Jung Kim · 7 shared papers, 2017–2025 · strength 1.19
  21. Jin Hee Kim · 6 shared papers, 2020–2026 · strength 1.16
  22. Do Hyun Park · 11 shared papers, 2017–2024 · strength 1.14
  23. Sang Hyun Shin · 12 shared papers, 2016–2021 · strength 1.03
  24. Se Jin Choi · 4 shared papers, 2022–2026 · strength 0.88
  25. Dongwook Oh · 5 shared papers, 2022–2026 · strength 0.81

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.